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Abstract: Tumor associated macrophages are an essential part of the tumor microenvironment.
Consequently, bone marrow-derived monocytes (BMDMs) are continuously recruited to tumors
and are therefore seen as ideal delivery vehicles with tumor-targeting properties. By using
immune cell depleting agents and macroscopic in vivo fluorescence imaging, we demonstrated
that removal of endogenous monocytes and macrophages (but not neutrophils) leads to an increased
tumor accumulation of exogenously administered BMDMs. By means of intravital microscopy
(IVM), we confirmed our macroscopic findings on a cellular level and visualized in real time the
migration of the donor BMDMs in the tumors of living animals. Moreover, IVM also revealed
that clodronate-mediated depletion drastically increases the circulation time of the exogenously
administered BMDMs. In summary, these new insights illustrate that impairment of the mononuclear
phagocyte system increases the circulation time and tumor accumulation of donor BMDMs.
Keywords: BMDM; depletion; phagocytes; competition; clodronate; intravital microscopy; fluorescence
1. Introduction
Recruitment of immune cells to the tumor microenvironment followed by successful recognition
of the tumor cells is essential for terminating tumor progression [1]. However, this fundamental
process can also contribute to the level of tumor malignancy [2,3]. This dual role of the immune system
in the development of a tumor has been described by the immunoediting theory and consists of three
consecutive phases: elimination, equilibrium and escape. During the elimination phase, most of the
tumor cells are killed by the immune system. In the next phase, the division rate of the remaining
tumor cells and the tumor killing rate of the immune system are in equilibrium. The final phase
starts when the immune system is no longer able to control the tumor cell growth [4]. Interestingly,
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this last stage of tumor development is also dependent on the infiltration of immune cells to form
an immune suppressive and hence, tumor permissive environment. We can exploit this immune
cell dependency of tumors by first collecting and loading immune cells with anti-cancer agents
and subsequently infusing them back into cancer patients. In this regard, monocytic cells are an
interesting cell type because of their tumor-homing characteristics [5] and the fact that monocytic
cells contribute to the pool of tumor associated macrophages (TAMs), which can constitute up to
50% of solid tumor masses [6]. These TAMs mainly differentiate from circulating Ly6C+ CCR2+
inflammatory monocytes which, in turn, originate from the bone marrow [7,8]. Despite the strong
reliance of solid tumors on recruiting circulating monocytes, we could previously not find an increased
accumulation of injected monocytes in mouse mammary tumors compared to other myeloid cell
populations [9]. We hypothesized that a tumor-homing competition between endogenous immune cells
and exogenously administered immune cells may have masked inherent differences in tumor-homing
capacities between different cell populations. As established solid tumors attract massive amounts
of immune cells, it is likely that the tumor vasculature is congested with multiple populations of
immune cells in the process of rolling, adhering and diapedesis. Endogenous immune cells can then
be considered as direct competitors of systemically administered cell-based therapies for trafficking
to the tumor microenvironment. In this study, we explored how biodistribution patterns of injected
primary bone marrow-derived monocytes (BMDMs) are affected by various regimens that deplete
endogenous immune cells. We demonstrated that depletion of macrophages and monocytes by
clodronate (CLO) liposomes increased the accumulation of exogenously administered BMDMs in
the tumor, lungs and spleen of mice. An increased accumulation of BMDMs was also seen in the
lungs, liver and spleen after specific depletion of Gr-1-positive cells (i.e., Ly6C+Ly6G- monocytes and
Ly6C+Ly6G+ neutrophils) [10]. However, anti-Ly6G-mediated depletion of endogenous neutrophils
prior to BMDM administration did not significantly increase the tumor-homing of BMDMs, nor did
this have a significant effect on the accumulation in other tissues. Furthermore, using a four color
intravital microscopy procedure, we confirmed our macroscopic observations and found that CLO
liposome pretreatment leads to an increased circulation time and diapedesis of injected BMDMs in
tumors of living mice.
2. Results
Ex vivo engineered immune cells have been considered for anti-cancer immunotherapy and as
cellular vehicles for targeted delivery of cargoes to tumors or other inflamed tissues [10–14]. However,
the effect of endogenous immune cells on the tumor-homing and diapedesis of exogenous immune cells
is not known. In this study, we pretreated (24 h beforehand) tumor-bearing mice with clodronate (CLO)
liposomes, anti-Gr-1 or anti-Ly6G antibodies to assess the role of the mononuclear phagocytic system
and specific subsets of myeloid cells on the distribution of exogenously administered DiD-labeled
BMDMs in living mice. Controls regarding the validity of the conducted experiments include initial
tumor size, antibody specificity, immune cell depletion and BMDM labeling efficiency (Supplementary
Figure S1). CLO liposomes-mediated depletion increased the tumor accumulation of BMDMs 24 h
(p = 0.0931) and 48 h (p = 0.0087) after their intravenous injection (Figure 1A,B,F,G and Supplementary
Figure S2J). In contrast, pretreatment with anti-Gr-1 antibodies did not significantly increase the
accumulation of BMDMs in the tumors (Figure 1A,B,F,G and Supplementary Figure S2K). Depletion
with CLO liposomes also slightly increased the amount of DiD-labeled BMDMs in the opposite
tumor-free mammary gland (p = 0.026 at 24 h and p = 0.0022 at 48 h), while anti-Gr-1 depletion
had no effect or even decreased the fluorescence in this region (p = 0.0173 directly after injection in
anti-Gr-1-pretreated mice) (Figure 1E and Supplementary Figure S2G,H).
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Figure 1. Depletion of the mononuclear phagocyte system increases the accumulation of exogenously 
injected bone marrow-derived monocytes (BMDMs) in the tumor and in other tissues. Mice were pre-
treated with PBS, clodronate liposomes (CLO), anti-Gr-1 (Gr-1) or anti-Ly6G (Ly6G) antibodies 24 
hours before administration of 106 DiD-labeled BMDMs. The total radiant efficiency was measured 
using macroscopic in vivo fluorescence imaging right before (pre) and directly after (post) BMDM 
injection as well as at 24 hours and 48 hours after injection. In (A), representative in vivo fluorescence 
images 48 h after BMDM injection are shown. The symbols represent the lungs (dashed line), the 
tumor (dotted circle), opposite mammary gland (asterisk), spleen (arrow) and presumed location of 
the liver (full line). (B–E) The fold change in BMDM accumulation immediately before (pre) and after 
(post) as well as at 24 and 48 hours after injection of DiD-labelled BMDMs were calculated relative to 
control mice that were pretreated with PBS (y = 1). (F) Directly after the last in vivo measurement, the 
fluorescence of each individual organ was measured ex vivo and compared to the PBS pretreated 
control mice (y = 1). (G) Representative ex vivo fluorescence images of the tumors and dissected 
organs. The depletion experiments were independently conducted. This explains the variation in 
fluorescence between the PBS groups in G and in Figure S1D-F. The error bars represent the standard 
deviations (n = 6). *p < 0.05, ** p < 0.01 compared to the respective PBS control at each separate time 
point. Individual measurements can be found in Supplementary Figure S2. 
We also investigated the BMDM accumulation patterns in the lungs and the liver-and-spleen 
region. Immediately after their intravenous injection, the BMDMs mainly accumulated in the lungs 
Figure 1. Depletion of the mononuclear phagocyte system increases the accumulation of exogenously
injected bone marrow-derived monocytes (BMDMs) in the tumor and in other tissues. Mice were
pre-treated with PBS, clodronate liposomes (CLO), anti-Gr-1 (Gr-1) or anti-Ly6G (Ly6G) antibodies
24 h before administration of 106 DiD-labeled BMDMs. The total radiant efficiency was measured
using macroscopic in vivo fluorescence imaging right before (pr ) and directly after (post) BMDM
injection as well as at 24 h and 48 h after injectio . In (A), repres ntative in vivo fluorescence images 48
h after BMDM inje tion are shown. The symbols repr sent the lungs (dashe line), the tumor (dotted
circle), opposite mammary gland (asterisk), spleen (arrow) and presumed location of the liver (full
line). (B–E) The fold change in BMDM accumulation immediately before (pre) and after (post) as well
as at 24 and 48 h after injection of DiD-labelled BMDMs were calculated relative to control mice that
were pretreated with PBS (y = 1). (F) Directly after the last in vivo measurement, the fluorescence of
each individual organ was measured ex vivo and compared to the PBS pretreated control mice (y = 1).
(G) Representative ex vivo fluorescence images of the tumors and dissected organs. The depletion
experiments were independently conducted. This explains the variation in fluorescence between the
PBS groups in G and in Figure S1D-F. The error bars represent the standard deviations (n = 6). * p < 0.05,
** p < 0.01 compared to the respective PBS control at each separate time point. Individual measurements
can be found in Supplementary Figure S2.
We also investigated the BMDM accumulation patterns in the lungs and the liver-and-spleen region.
Immediately after their intravenous injection, the BMDMs mainly accumulated in the lungs of immune
cell depleted and non-depleted mice (Supplementary Figure S2A–C). After 24 h, a redistribution of
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the BMDMs from the lungs to the tumor and liver-and-spleen region was apparent in all the mice
(Supplementary Figure S2A–F). Nevertheless, significantly more BMDMs remained in the lungs of
mice pretreated with CLO liposomes compared to mice pretreated with PBS (p = 0.00411 at 24 h and
at 48 h) (Figure 1C). Moreover, ex vivo imaging of the lungs after euthanasia showed that both CLO
liposomes and anti-Gr-1-pretreated mice still contained significantly more BMDMs than PBS control
mice (p = 0.0022 and p = 0.0043, respectively; Figure 1F). As mentioned, BMDMs started to accumulate
in the liver-and-spleen region of all mice after 24 h and even more BMDMs accumulated in this region
when mice were pretreated with CLO liposomes (p = 0.0026 at 24 h and p = 0.0043 at 48 h, Figure 1D
and Supplementary Figure S2). Interestingly, ex vivo imaging of both organs separately demonstrated
that only the spleen of CLO liposomes-pretreated mice contained increased BMDMs compared to the
PBS controls (p = 0.0022) whereas anti-Gr-1-treated mice exhibited increased BMDMs in both the liver
(p = 0.0043) and the spleen (p = 0.0173, Figure 1F).
In a subsequent experiment, we evaluated whether depletion of endogenous cells that are not
related to the injected cells could influence the BMDM biodistribution. To that extent, we specifically
depleted neutrophils in tumor-bearing mice using anti-Ly6G antibodies (Supplementary Figure S1J).
Interestingly, neutrophil depletion did not significantly alter the in vivo tumor-homing of BMDMs, nor
their accumulation in other tissues (Supplementary Figure S2). Likewise, ex vivo imaging of excised
tumors and organs of anti-Ly6G pretreated mice demonstrated that the number of fluorescent BMDMs
in these tissues was not different from the PBS-pretreated control mice (Figure 1F, Supplementary
Figure S3).
Macroscopic in vivo fluorescence imaging is often used to monitor the in vivo migration of cells.
However, this technique does not give information about the diapedesis efficiency as it cannot reveal
the microscopic location of exogenous cells in tissues. Therefore, intravital microscopy (IVM) was
used to further evaluate the increased tumor accumulation of BMDMs after pretreatment with CLO
liposomes (Supplementary Figure S4). We developed an IVM protocol that enabled simultaneous
visualization of nucleated cells, blood vessels, endogenous macrophages and the intravenously injected
DiD-labeled BMDMs. This protocol allowed us to discriminate intact BMDMs from endogenous
macrophages that internalized BMDM fragments. Circulating immune cells in the blood vessels of
tumors were visualized by employing fast imaging (0.6 s/frame), allowing us to identify differences
regarding BMDM clearance between PBS- and CLO liposomes-pretreated mice. Exogenous BMDMs
were rapidly (<30 min) cleared in PBS-pretreated mice (Figure 2A and Supplementary video S1) and
only a few BMDMs remained in circulation after 1.5 h. In contrast, in mice pretreated with CLO
liposomes, exogenous BMDMs displayed a prolonged blood circulation with many cells visible 6 h
as well as 48 h after BMDM injection (Figure 2B and Supplementary videos S1 and S2). Importantly,
pre-treatment with CLO liposomes also increased the diapedesis (extravasation) of the BMDMs at
the tumor. This observation was made as soon as a few hours post injection and was even more
evident at 48 h post injection, where much more fluorescent BMDMs were detected in the extravascular
compartment of CLO liposomes-pretreated mice (Figure 2C,D). These extravasated BMDMs were
mainly found around small blood vessels. In addition to extravasated DiD-labeled BMDMs, we also
found BMDMs that stuck to the blood vessel walls and were presumably in the process of diapedesis
(Supplementary videos S2, S3 and S4). To further confirm that the DiD-labeled structures were intact
BMDMs, double labeled BMDMs (DiD and Hoechst) were injected together with an endogenous
macrophage tracer (40 kDa TMR-dextran) in tumor-bearing mice (Figure 3A–F). Clearly intact BMDMs
(red and blue colored cytosol and nucleus, respectively) (Figure 3F insert) as well as intact BMDMs
with a more speckled fluorescence pattern (Figure 3D insert) could be observed by IVM (see also
Supplementary video S3). This experiment also demonstrated that endogenous macrophages are
frequently positioned in close proximity to blood vessels and that these cells have a more spread-out
morphology (longest diameter ranging from 18 to 29 µm) compared to the injected BMDMs (about
8–10 µm; Figure 3A–D). Moreover, in addition to DiD+/Hoechst+ BMDMs, some circulating cells
appear to be only Hoechst+ or only DiD+. This can be attributed to imperfect staining or imaging
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artifacts. Smaller DiD+ particles were also seen in association with endogenous macrophages (asterisk
in Figure 3A–D and Supplementary video S3), indicating horizontal dye transfer. Image analysis was
performed on the IVM data (Figure 3H) to quantify the differences in tumor accumulation of BMDMs
in PBS- and CLO liposomes-pretreated mice. This revealed a clear trend in increased accumulation of
exogenously administered BMDMs in tumors of CLO liposomes-pretreated mice compared to tumors
of PBS-pretreated mice. The increased fluorescence originated from uniformly as well as irregularly
labeled BMDMs (mean in vitro diameter of 9.4 µm; (Figure 3F,H).
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Figure 2. Depletion of the mononuclear phagocyte system prolongs the circulation of exogenously
administered BMDMs. Mice were first pretreated with either PBS or CLO liposomes. After 24 h,
106 DiD-labeled B DMs were injected and their appearance in the tumor microenvironment was
monitored by intravital microscopy. In PBS- r tr ted mice (A), only a few circulating DiD-labeled
BMDMs (red, arrows) can be seen 90 min after their administration, whereas 6 h after their dminist ation
many BMDMs were still detected in the bloo of CLO liposomes-pretr ated mice (B) (see also
accompanied Supplementary video S1). Hoechst (blue) and 40 kDa TMR-dextran (green) were
systemically injected before imaging to discriminate endogenous macrophages (green) from exogenous
BMDMs (red). Residual 40 kDa TMR-dextran in the blood within the first hours after injection allows
visualization of the blood vessels as well. Two days after their injection, considerably more BMDMs
can be seen in the tumors of mice pretreated with CLO liposomes (D) compared to PBS pretreated
control mice (C). Most of these extravasated BMDMs are present near capillaries. The green color
in (C) and (D) originates from 2 MDa FITC-dextran, a fluorescent vascular tracer. Scale bars: 50 µm.
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Figure 3. Depletion of the mononuclear phagocyte system increased the accumulation of BMDMs
in the tumor interstitium. Mice were first pretreated with either PBS or CLO liposomes. After 24 h,
106 BMDMs that were labeled with both DiD (red) and Hoechst (blue) were injected in mice pretreated
with CLO liposomes. After 60–90 min, the appearance of these double labeled BMDMs (white arrows
in (A–D) in the tumor microenvironment was imaged by intravital microscopy. The insert in panel D
demonstrates that non-uniformly labeled BMDMs can appear as small fluorescent speckles. The used
labeling strategy allows separation of injected Hoechst/DiD-positive BMDMs (7.8 µm) from larger
(18–29 µm) 40 kDa TMR-dextran-positive endogenous phagocytes (yellow). The white numbers in panel
A represent the long diameter (in µm) of several endogenous macrophages lining the blood vessels.
The sterisk in p nels A–D shows an endogenous phagocyte suspected of engulfing DiD-labeled cell
fragments (See lso Supplementary video S3). Panel D was obtained by merging pan ls (A–C) w th an
addit onal layer of 2 MDa FITC dextran (green) to delineate the loo vessels. (G) Size distributi n of
cultured DiD-labeled BMDMs. BMDMs w re labele with DiD and after 2 days of culture, confocal
fluorescence images w re taken and the size distribution of the cells was analyzed using Image J
(bin size of 2.5 µm). A mean BMDM diameter of 9.4 µm was determined and fluorescent particles
smaller than 2.5 µm were identified as background noise. (H) The size distribution of exogenously
administered BMDMs that arrived in the tumor was quantified by automated particle counting on
IVM images such as panels (E) and (F). The data clearly show an increased accumulation of BMDMs in
tumors of mice that were pretreated with CLO liposomes. Scale bars: 50 µm; the error bars represent
standard deviation, n = 3.
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3. Discussion
The growing interest in cell-based tumor therapies has revealed critical knowledge gaps in our
understanding of the basic principles of immune cell recruitment to the tumor microenvironment [15–17].
Our investigation aimed to address one of these gaps by evaluating how the presence of endogenous
immune cells affects the recruitment of exogenously administered immune cells to tumors. In more
detail, we studied how depletion of specific myeloid leukocyte populations influenced the
tumor-homing and tissue distribution of exogenous bone marrow-derived monocytes (BMDMs).
By combining advanced macroscopic and microscopic in vivo fluorescence imaging techniques,
we revealed that depletion of macrophages and monocytes increased the blood circulation time,
tumor-homing and extravasation of BMDMs at the tumor. In contrast, depletion of neutrophils,
which do not belong to the monocytic lineage, did not increase the tumor accumulation of BMDMs.
This suggests that the tumor accumulation of exogenous immune cells might be impeded by endogenous
cells of the same lineage.
Macroscopic in vivo fluorescence imaging is limited by the tissue penetrance of the used excitation
light and should therefore be complemented with ex vivo measurements of excised organs. In addition,
these macroscopic techniques do not allow discrimination of intact cells from labeled cell fragments
and do not provide information about the exact histological location of the emitted fluorescence.
Therefore, we complementary used intravital microscopy (IVM) to confirm our findings and to further
investigate the effect of CLO liposomes on the migration process at a microscopic level. Although
many of the extravascular DiD-positive cells appeared uniformly stained and thus intact, smaller-sized
fluorescent speckles could also be seen. Through injection of Hoechst+/DiD+ double labeled BMDMs,
we demonstrated that these speckles can originate from non-uniformly stained BMDMs (Figure 3D).
However, endogenous macrophages that phagocytosed DiD-labeled cell fragments (e.g., apoptotic
bodies) can also appear as fluorescent speckles. Injecting 40 kDa TMR-dextran before imaging allowed
us to distinguish injected DiD-positive BMDMs from secondary labeled DiD+/TMR+ phagocytes on
IVM images and movies. Moreover, using image analysis software, we were able to quantify the
BMDMs in the tumors and to determine their size distribution (Figure 3H). The data obtained from
IVM confirmed that pretreatment with CLO liposomes increased the extravascular accumulation
of BMDMs in the tumor. Moreover, IVM also revealed a drastically prolonged BMDM circulation
time in mice pretreated with CLO liposomes (Figure 2A,B). This can explain the increased number of
DiD-labeled BMDMs seen at the tumor-free mammary gland of mice pretreated with CLO liposomes
(Figure 1E). Weisser et al. (2012) made a similar observation in an experimental colitis model [18].
In their model, gut macrophages were depleted via intraperitoneal injection of CLO liposomes and
polarized BMDMs were intravenously injected. Subsequent histological staining demonstrated that
the exogenously administered BMDMs repopulated the inflamed colon, indicating that the increased
infiltration of BMDMs after a depletion regimen can be applied to different inflammatory-based
settings. However, these imaging techniques only confirm the presence of injected cells in the tumor.
More elaborate research is needed to adequately assess their functional properties after arrival in the
tumor. While the possibility of endogenous immune cell competition on the recruitment efficiency of
adoptively transferred myeloid cells has been briefly mentioned before [19], to our knowledge, the
effect of endogenous myeloid cell depletion on the migration of exogenous BMDMs towards the tumor
has never been studied.
The exogenous BMDMs did not only accumulate in the tumors. In vivo macroscopic fluorescence
imaging revealed that a large portion of the intravenously injected BMDMs immediately accumulate
in the lungs (Supplementary Figure S2). Given that the lungs receive the complete cardiac output
and exhibit narrow capillary diameters, it is not surprising that they capture a substantial part of
the injected cells [20]. Yet, we did not observe any symptoms of respiratory distress in this study,
nor did we see such symptoms when mice were imaged over a period of 20 days [9]. Over the
following days, a redistribution of the BMDMs from the lungs to the tumor and liver-and-spleen
region occurred. The latter organs are typical accumulation sites due to their large size and vascular
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volume [21]. Interestingly, this reallocation to other organs occurred significantly more slowly in CLO
liposomes-depleted mice than in PBS or antibody (anti-Gr-1 or anti-Ly6G) depleted mice. This can
be explained by either a stronger and longer adherence of injected BMDMs in the lungs or by the
prolonged circulation of BMDMs in CLO liposomes-pretreated mice (Figure 2B). Because the lungs
act as a margination pool for leukocytes [22,23], it is not a surprise that the BMDMs are captured by
this organ.
In vivo, anti-Gr-1 pretreatment demonstrated no differences compared to PBS mice. However,
ex vivo imaging of the individual organs revealed significantly higher BMDMs in the lungs, liver
and spleen, but not the tumors of anti-Gr-1 pretreated mice (Figure 1B–F). Still, we have to interpret
these data with caution. Antibodies are known to have a longer serum half-life (around 1–3 weeks)
than PEGylated CLO liposomes (about 20 min). Therefore, these antibodies were most likely still
present when the donor BMDMs were injected. Binding of the anti-Gr-1 antibodies to the BMDMs
would then lead to opsonisation and enhanced clearance of the injected Ly6C-positive BMDMs in mice
pretreated with antibodies but not in CLO liposomes-pretreated mice (Figure 1F) [9,24–26]. Our former
experiments have indicated that a large percentage of the BMDMs obtained with our protocol are
Ly6C-positive [9], making this theory plausible. Furthermore, the significantly lower fluorescence
signal of the BMDMs in the tumor-free mammary gland of anti-Gr-1 pretreated mice is indicative of a
higher clearance of BMDMs and hence underpins the hypothesis that residual anti-Gr-1 antibodies
also depleted the exogenous BMDMs (Figure 1E). Of note, this critical remark does not apply to the
anti-Ly6G-mediated depletion since BMDMs do not express this marker [10].
Removal of endogenous macrophages by CLO liposomes increased the circulation time of
exogenous BMDMs (Figure 2B). Our experiments did not allow the determination of whether the
increased presence of tumor-associated BMDMs after pretreatment with CLO liposomes resulted from
a decline in endogenous competition for vascular binding sites or whether it was merely due to more
BMDMs circulating. The feasibility to deplete immune cells in humans has been demonstrated in
the field of, e.g., CAR T cell therapy, where the current view is that endogenous T cells might act
as “cytokine sinks”, i.e., they deprive the injected CAR T cells from the cytokines that are necessary
for adequate activation and proliferation [27–29]. Therefore, a common approach to increase the
clinical efficacy of CAR T cell therapy is to perform lymphodepletion prior to infusing the genetically
modified lymphocytes. In analogy with the lymphodepletion regimens before CAR T cell therapy,
one can wonder whether it is sensible to administer BMDMs before or after monocyte-depleting
nonmyeloablative anti-cancer treatments [30–32].
Macrophages play an important role in efferocytosis, the removal of dead or dying blood cells.
Therefore, it is tempting to speculate that a portion of the exogenous BMDMs are phagocytosed by
endogenous macrophages and that depletion of these phagocytes prevented compromised exogenous
BDMDs from being cleared from the circulation. Compromised and senescent cells are cleared by
phagocytic cells after recognition of “eat me” cell surface markers (e.g., phosphatidylserine [33,34]
or oxidized lipids [35]) on apoptotic cells. We hypothesize that the ex vivo manipulation of the
BMDMs induced the expression of clearance markers in a fraction of the cells, despite demonstrating
above 95% cell viability upon injection (trypan blue). Ideally, the efficiency of future adoptive cell
transfer experiments can be increased by first clearing this ill-fated population before administration.
Alternatively, masking phosphatidylserine [36] or incorporation of “don’t eat me” signals such as
CD47 can be used for therapeutic purposes [37].
In the broad context of drug delivery, immune cells are interesting drug delivery vehicles as
they are actively recruited to sites of inflammation (e.g., the tumor microenvironment). They can be
loaded with therapeutic agents or transfected with DNA or mRNA vectors that encode a therapeutic
protein [11,19]. Furthermore, the release of the therapeutic cargo can initiate tumor cell destruction,
which leads to more inflammation and further recruitment of the cell vehicles to the site of interest [11].
A second argument of using cells as delivery vehicles over, e.g., nanoparticles, is that the cells can
actively penetrate the tumor tissue whereas nanoparticles are restricted to passive diffusion and hence,
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are often impeded by the high interstitial pressure seen in many solid tumors [38,39]. However,
a disadvantage of cell-based drug delivery systems is their complicated production process and the
need for cells that are not recognized as foreign by the patient. From our data, it appears that cell
recognition might also apply to autologous cells that haven undergone manipulation. Considering the
increased interest in immune cell therapies over the last decade, addressing this lack in understanding
could potentially help improve the unresolved recruitment problem which many of these therapies
are facing.
4. Materials and Methods
4.1. Animals
All the procedures in this study were approved by the Ethical Committee of the Faculty of Veterinary
Medicine and the Faculty of Bioscience Engineering of Ghent University, Belgium (EC 2015/100) and the
Norwegian Food Safety Authority (19/26187). Female Balb/cJRj mice, aged 6–8 weeks, were purchased
from Janvier Labs (Paris, France) and housed in a temperature and humidity-controlled room while
being kept on a 12 h:12 h reverse light/dark cycle. Ad libitum access to low-fluorescence food (Envigo,
Boxmeer, Netherlands, #T.2018.12) and water was provided. Mice were ear marked and randomly
assigned to experimental conditions. All manipulations were performed on a heated platform and
under general anesthesia using 5% isoflurane (Zoetis, Louvain-la-Neuve, Belgium, #B506) at 4 L/min
oxygen for induction and 1.5–2% isoflurane at 0.5–1 L/min oxygen for maintenance.
4.2. Tumor Model
Luciferase-positive 4T1 mammary carcinoma cells were cultured in complete medium consisting
of DMEM/F12 (Thermo Fisher, Aalst, Belgium, #21041-025) supplemented with 10% heat inactivated
FBS (VWR, Leuven, Belgium, #S181H-500) and 1% penicillin/streptomycin (Thermo Fisher, Aalst,
Belgium, #15070-063). After at least 3 passages, cells were trypsinized and washed twice in Dulbecco’s
Phosphate-Buffered Saline (Thermo Fisher, Aalst, Belgium, #14190-144). Subsequently, 1 × 105 cells
in 100 µL DPBS, were injected in the 4th right fat pad using a 29 G insulin syringe (Terumo, Leuven,
Belgium, #BS05M2913). Tumor growth was verified by administering 150 µL D-luciferin (15 mg/mL
DPBS) (Goldbio, St-Louis (MO), USA, #LUCK-1G) subcutaneously followed by bioluminescence
imaging after 10 min with an IVIS Lumina II system (PerkinElmer). Cell migration experiments were
initiated 10 days post tumor inoculation. At this time point, tumors reached an average diameter of
4.0–4.8 mm. This average tumor diameter was obtained by measuring both perpendicular diameters
twice and then averaging the total of 4 measurements.
4.3. Bone Marrow-Derived Monocytes
Bone marrow cells were isolated from female Balb/cJRj mice according to the method described
by Amend et al. (2016) [40]. Mice were induced with isoflurane and sacrificed via cervical dislocation.
Next, femurs and tibias were dissected, sterilized 10 s in 70% Disinfectol (Chem-lab NV, Zedelgem,
Belgium, #CL00.0112.2500) and rinsed in sterile DPBS before snapping the bones in half and transferring
these to punctured 0.5 mL Eppendorf tubes that were placed in empty 1.5 mL Eppendorf tubes. After
centrifugation for 15 s at 10,000× g, recovered pellets were resuspended 40 s in 150 µL ACK RBC
lysis buffer (Thermo Fisher, Aalst, Belgium, #A10492-01) and neutralized by adding 1 mL complete
medium. Finally, these cells were centrifuged for 5 min at 400× g and resuspended in complete medium
(DMEM/F-12, 10% FBS, 1% penicillin/streptomycin).
Bone marrow-derived monocytes (BMDMs) were obtained by seeding 5 ml RBC-depleted bone
marrow cells (1–2 × 106 cells/mL) in complete medium supplemented with 20 ng/mL M-CSF (VWR,
Leuven, Belgium, #21-8983-U010). Cells were cultured for 5 days in an untreated 9 cm petri dish (VWR,
Leuven, Belgium, #391-0457) to prevent adherence-induced differentiation [41]. Fresh culture medium
was added 3 days post-seeding (3 mL per well). After 5 days, cells in suspension were collected and
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adherent cells were detached and collected by 30 min detachment in the protease/collagenase cocktail
AccutaseTM (Biolegend, Koblenz, Germany, #424301) and subsequent neutralization by addition of
warm complete medium. Adherent cells and cells in suspension were pooled.
4.4. Cell Labeling
Labeling with Vybrant DiD (Thermo Fisher, Aalst, Belgium, #V22887) was performed by adding
1 µL of 2 mM stock dye to cells suspended in 200 µL DPBS at a concentration of 5 × 106/mL.
After vortexing, the cells were incubated for 20 min at 37 ◦C in darkened 15 mL tubes. Subsequently,
they were centrifuged for 5 min at 400× g and resuspended in warm complete medium. Next, cells
were washed twice in DPBS and resuspended in appropriate downstream buffer.
4.5. Systemic Injection
One hour before administration, clodronate (CLO) liposomes or control liposomes (Liposoma,
Amsterdam, The Netherlands, #CP-005-005) were kept at room temperature. Per mouse, 200 µL
liposomes (50 µg/g) was administered retro-orbitally after vortexing, using a 29 G insulin syringe
(VWR, Leuven, Belgium,). Likewise, labeled BMDMs were vortexed prior to injection with a 29 G
insulin syringe. Unless noted otherwise, 100 µL of cells suspended in DPBS were injected in the right
orbital plexus of anesthetized mice at a concentration of 10 × 106/mL [42,43]. Anti-Gr-1 (Bioxcell,
Lebanon, USA, #BE0075) or anti-Ly6G (Bioxcell, Lebanon, USA, #BE0075-1) depleting monoclonal
antibodies were administered intraperitoneally at a dose of 250 µg per mouse in 100 µL DPBS [44].
4.6. Flow Cytometry
Cells were suspended at 1 × 106/mL in 200 µL staining buffer (DPBS + 2%FBS + 2mM EDTA)
followed by adding 0.5 µL anti-CD16/32 FcR blocking antibodies (BD, #553142) [45]. After 10 min
incubation at 4 ◦C additional fluorescently labelled antibodies against the selected markers were
added and the cells were further incubated at 4 ◦C for 15 min. Subsequently, they were washed by
adding 1 mL staining buffer per dark 1.5 mL Eppendorf tube and centrifuged for 5 min at 400× g.
The resulting pellet was resuspended in 200 µL staining buffer. The DNA intercalating dye 7-AAD
(Biolegend, Koblenz, Germany, #420403) was used to exclude dead cells. A weekly calibrated and
validated C6 Accuri (BD) or Cytoflex (Beckman Coulter, Brea, CA, USA) flow cytometer was used
for acquisition. BD Accuri C6 software (version 1.0.264.21, San Jose, CA, USA) was used for analysis.
The following selected antibodies were used (from Biolegend, San Diego, CA, USA): anti-Ly6C-FITC
(#128005), anti-CD11b (#101211). Anti-F4/80-R-PE was ordered from Biorad (#MCA497PET). Doublets,
debris and dead cells were excluded in all analyses.
4.7. In Vivo and Ex Vivo Fluorescence Imaging
In vivo fluorescence imaging of the DID-labeled cells was performed with an IVIS Lumina II
system (PerkinElmer, Waltham, MA, USA) using the 740/780 nm filter pair. All the mice were ventrally
shaven from the cervical to the pubis region before imaging. The accumulation of the labeled cells in the
tumor, lungs, liver and spleen was quantified using the total radiant efficiency (p/s/µW/cm2). Reported
values were normalized to the background fluorescence of each individual mouse before injection of
BMDMs. Since spleen mobility can cause spleen and liver to overlap in vivo, the fluorescence of these
organs was combined into one region of interest (ROI). ROI dimensions were kept constant for all
the mice.
4.8. Intravital Microscopy
Female wild type Balb/c mice were orthotopically inoculated in the 4th mammary fat pad with
1–1.5 × 106 4T1 cells in 100 µL PBS or 1:1 0.9% NaCl:matrigel (Corning, Corning, NY, USA, #354262).
Ten to fourteen days later, mice were anesthetized (subcutaneous injection with a mixture of fentanyl
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(0.05 mg/kg), medetomidine (0.5 mg/kg), midazolam (0.5 mg/kg) and water (2:1:2:5) at a dose of 0.1 mL
per 10 gram of body weight) and their tumors were carefully detached as a “skin flap” from the
abdominal wall without damaging the blood vessels. After the fat tissue surrounding the tumor
was removed, the “skin flap” with the tumor was mounted on a custom-made imaging platform
and then positioned on a heated (30 ◦C) microscope stage (Supplementary Figure S4). Twenty-four
hours before imaging, mice were pretreated with either CLO liposomes or PBS. In addition to the
DiD-labeled BMDM injection, the mice were also intravenously injected with 100 µL Hoechst 33342
(Sigma, #B2251-100MG, 2 mg/mL), 40 kDa TMR-dextran (#42874-1G, Sigma, 10 mg/mL) and/or 2 MDa
FITC-dextran (#FD2000S, Sigma, 10 mg/mL). In the double labeling experiments, BMDMs were first
labeled with Hoechst (100 ng/mL, 45 min at 37 ◦C) followed by labeling with DiD (20 min at 37 ◦C)
and neutralizing by adding 2 volumes of complete medium. The stained BMDMs were washed twice
in PBS before injection. Intravital microscopy was performed on a Leica SP8 confocal microscope
(Leica microsystems, Wetzlar, Hesse, Germany) using a 20 × 0.75 air objective. The system is equipped
with an external UV laser, a tunable white light laser and a tunable band pass detection system
allowing the detection of four colors simultaneously: Hoechst (405/430–470 nm); GFP or FITC-dextran
(488/505–520 nm); TMR-dextran (565/575–625 nm); DiD-BMDMs (644/654–700 nm). Data acquisition
was performed with Leica LASX software. Image J (FIJI) version 1.52n was used for the image assembly
and quantification of fluorescence occurred as follows: channel 3 (endogenous phagocytes labeled
with TMR-dextran) was first subtracted from channel 4 (DiD-BMDMs) to exclude DiD-fluorescence
associated with phagocytosis. Next, a black and white threshold was set, the image was converted to a
binary mask and watershed was applied. Lastly, the number of particles and the areas above 1 µm2
were determined via the analyze particles command. Particle diameters were determined via the area
of a circle (A = pi·r2).
4.9. Statistics
Statistics were performed in Prism Graphpad (version 6.01, Graphpad Software, San Diego, CA,
USA). Unless otherwise specified, two-way non-parametric Mann–Whitney rank tests were used.
p-values lower than 5 percent were used to indicate statistical significance. The reported values
represent averages ±standard deviation (SD).
5. Conclusions
Taken together, our results indicate that depletion of the mononuclear phagocyte system via
CLO liposomes significantly increases the circulation time of systemically injected BMDMs and that
a higher presence of these BMDMs can be seen in the tumor, the lungs and the spleen after 2 days.
In contrast, depletion of endogenous immune cells that belong to another immune cell lineage than the
exogenously administered BMDMs did not affect their tumor accumulation. We hypothesize that a
subset of BMDMs expose “eat me” signals on their surface resulting from their ex vivo manipulation.
By depleting the mononuclear phagocytic system, we might have prevented these tagged cells being
massively removed upon injection.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6694/11/11/1752/s1,
Figure S1: The initial tumor sizes and the injected doses of DiD-labeled BMDMs in each immune cell depletion
group and respective control group were determined to ensure that changes in tumor homing of BMDMs were
not biased by significant differences in tumor size or injected BMDM dose. In addition, blood was collected via
cardiac puncture to verify functional depletion via flow cytometry. Figure S2: Total radiant efficiency (p/s/cm2/sr)
measured by in vivo macroscopic fluorescence imaging at different organs and the tumor immediately before
(pre) and after (post) DiD-BMDM injection as well as at 24 h and 48 h after injection of DiD-labeled BMDMs.
Figure S3: Total radiant efficiency (p/s/cm2/sr) of tumors and organs excised from mice euthanized 48 h after
injection of DiD-labeled BMDMs. Figure S4: Setup of the intravital microscopy (IVM) procedure. Video S1: Real
time visualization of circulating DiD-labeled BMDMs in mammary fat pad tumors of PBS and CLO liposomes
pretreated mice. Video S2: Real-time visualization of long-term circulating DiD-labeled BMDMs in mammary
fat pad tumors of CLO liposomes-pretreated mice. Video S3: Z-stack (starting superficial) through a mammary
fat pad tumor of a CLO liposomes-pretreated mouse that was injected with Hoechst (blue)/DiD (red) double
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labeled BMDMs. Video S4: Z-stacks (starting superficial) through mammary fat pad tumors of PBS- and CLO
liposomes-pretreated mice that were injected with DiD-labeled BMDMs.
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